Mechanism of Action: Triple Receptor Agonist Retatrutide is a synthetic peptide that activates three key metabolic receptors: GLP-1 (Glucagon-Like Peptide-1) Enhances insulin secretion, suppresses appetite, delays gastric emptying GIP (Glucose-Dependent Insulinotropic Polypeptide) Boosts insulin response, improves insulin sensitivity, may support lipid metabolism Glucagon Receptor (GCGR) Elevates energy expenditure, promotes fat oxidation, and may reduce liver fat This triple agonist profile delivers synergistic effects on glycemic control, fat loss, and metabolic health, making Retatrutide the most advanced incretin-based peptide in development
Gastroprotection & Cytoprotection : Consistent with its origin, BPC-157 has repeatedly reduced gastric and intestinal lesion severity in preclinical models and supported mucosal closure.[3] Nitric-Oxide System Balancing : BPC-157 has normalised haemodynamics in settings of both nitric-oxide deficiency and excess, pointing to a homeostatic effect on vascular tone and tissue perfusion
Abstract Impaired redox metabolism is a key contributor to the etiology of many diseases, including primary mitochondrial disorders, cancer, neurodegeneration and aging
Supports Liver Function: A healthier liver means better hormone metabolism and elimination
In vitro functional assays, including luciferase and cAMP assays, were performed on cell lines expressing human and rat amylin and calcitonin receptors
